O f the clinical complications of cirrhosis, hepatic encephalopathy (HE) is the most devastating. HE is a spectrum of reversible cognitive changes ranging from minimal HE (MHE) (mild inattention and deficits of executive function) to overt HE (disorientation to coma). More than 40% of patients with cirrhosis develop HE, which increases mortality, falls, motor vehicle accidents, and has a significant psychosocial impact. 1 Early recognition is crucial. Patients with cirrhosis are recommended to receive an assessment for MHE. 2 To diagnose MHE, one must consult a neuropsychologist for tests that are administered and scored against local reference data. 2 Point-of-care tests (eg, EncephalApp) are available but also derive diagnostic cut-off values from the same data.
3 MHE thus is diagnosed by performance relative to age, sex, and, frequently, education-matched controls. [2] [3] [4] Data are limited by whether cut-off values derived from one population's controls generalize to another. Control performance has been characterized in Mexico and Europe, 2,4 but representative US data are lacking. Herein, we characterize factors that may confound psychometric test interpretation in a nationally representative cohort.
Methods
The Third National Health and Nutrition Examination Survey was a nationally representative crosssectional survey conducted from 1988 to 1994, in which randomly selected subjects aged 20 to 59 years (n ¼ 4924) underwent neuropsychometric testing using the Neurobehavioral Evaluation System 2 (NES2). 5 The NES2, a computerized cognitive function battery, consists of 3 components: a simple reaction time test (SRTT) (measures visuomotor speed); symbol digit substitution test (SDST) (measures symbol coding speed); and serial digit learning test (SDLT) (measure of working memory and learning). The NES2 is not used for the diagnosis of MHE, however, it is very similar to standard psychometric tests. 3 We identified 675 persons with definitive chronic liver disease (CLD), including chronic viral hepatitis (hepatitis C RNA or hepatitis B surface antigen), nonalcoholic steatohepatitis (NASH) (hepatosteatosis by ultrasound with abnormal transaminase levels), and alcoholic liver disease (ALD) (>14 drinks/wk and abnormal transaminase levels). An additional 939 individuals were identified as having suspected CLD based on abnormal alanine aminotransferase levels (males, >30 IU/L; women, >19 IU/L), aspartate aminotransferase levels (>33 IU/L), or alkaline phosphatase levels (>100 IU/L). We calculated the aspartate aminotransferase-platelet ratio index, a sensitive, nonspecific, fibrosis risk index. We investigated associations with composite NES2 scores using weightadjusted univariate and multivariate linear regression.
Results
The cohort represented a national population of 62.1 million adults aged an average of 36.9 years, 52% women, and 77% Caucasian. Definitive CLD was present in 11.2% (8.4% NASH, 2.8% viral hepatitis, and 2.6% ALD), and an additional 17.0% had suspected CLD, corresponding to an estimated 14 and 21 million adults aged 20 to 59, respectively. Definitive and suspected CLD was associated with an increase of 0.26 and 0.24 SD of the composite NES2 score (worse performance), and 0.14 and 0.14 SD after adjusting for potential confounders, respectively ( Table 1 ). The magnitude of the association of CLD with NES2 score was second to diabetes in multivariate analysis, with the strongest association noted among NASH patients. Other significant associations included age, sex, education, smoking, alcohol, and body mass index. Suspected CLD was associated with all NES2 domains (b ¼ 0.09, 0.09, and 0.12 SD for SDST, SDLT, and SRTT, respectively) in multivariate analysis; definitive CLD was associated significantly with the SDST (b ¼ 0.12 SD) and SDLT (b ¼ 0.12 SD), but not with SRTT components.
Discussion
These data from a nationally representative American cohort offer 3 novel findings. First, clinical features of healthy controls such as age, sex, education, body mass index, diabetes, smoking, and alcohol influence cognitive test performance. The prevalence of these factors varies substantially between populations but seldom are considered when matching controls to create diagnostic cut-off values for MHE. Second, although few subjects had probable cirrhosis (per the aspartate aminotransferase-platelet ratio index), the presence of CLD (ALD, hepatitis C, or NASH) was associated with worse cognitive performance, which suggests that factors beyond cirrhotic physiology may explain the cognitive changes observed in comparison with controls. Third, because comorbidities and specific liver diseases impact cognition independent of cirrhotic physiology, these conditions may affect psychometric test interpretation in afflicted patients with cirrhosis. For example, the vast majority of studies of MHE exclude patients with ALD. 3, 6, 7 Our data suggests that cut-off values derived from non-ALD patients with cirrhosis may not be applicable for patients with ALD.
In conclusion, generalizable psychometric testing using reference data requires careful control matching. The pitfalls of control matching are substantial. The impact of CLD itself, alcohol, obesity, diabetes, and smoking on cognitive test performance may deserve future study. To maximize both specificity and generalizability, cut-off values for MHE could be derived not from a proxy-comparing psychometric testing performance with controls-but from clinical outcomes. What matters most about a test is the ability to predict overt HE, not to compare cognitive function with a noncirrhotic subject. Future studies should determine cognitive test cut-off values using outcome prediction from longitudinal cohorts of patients at risk for the development of overt HE. All univariate and multivariate regression analyses were adjusted for sampling weights. b Coefficient referenced to mild-to-moderate drinking. Alcohol consumption is excluded in the multivariate analysis with CLD because it was used to define alcoholic CLD. c Suspected CLD was defined by abnormal liver enzymes using the following cut-off values: alanine aminotransferase (males >30 IU/L, women >19 IU/L), aspartate aminotransferase (>33 IU/L), or ALP (>100 IU/L). d Subclasses of CLD were not mutually exclusive.
